

References

L-87

1. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Non-Small Cell Lung Cancer (version 2.2017) 2016 National Comprehensive Cancer Network, Inc.
2. Gene summary on the ALK gene. Genetics Home Reference. Accessed 11/20/2014.
3. National Human Genome Research Institute. Fluorescence in-situ hybridization (FISH) Accessed 11/20/2014.
4. DiMaio M, De Marinis F, Hirsch FR, et al. Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (Review). *Int J Onc.* 2014; 45: 509-515.
5. Alexander RE, Montironi R, Lopez-Beltran A, et al. EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. *Mod Pathol.* 2014; 27: 107-112.
6. Ettinger DS, Wood DE, Akerley W, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer. V4. 2016.
7. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Arch Pathol Lab Med.* 2013; 137(6): 828-860.
8. Leigh NB, Rekhman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. *J Clin Oncol.* 2014; 32(32): 3673-3679.
9. Tan C, Lim T, Lim T, et al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. *Oncotarget.* 2016; 7(17): 23251–23262.
10. Ma D, Wang Z, Yang L, et al. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. *Oncotarget.* 2016; 7(39): 64410–64420.
11. Hongmei L, Huang M, Xu Y, et al. Clinical analysis of continuing crizotinib treatment beyond disease progression in ALK-positive non-small-cell lung cancer patients. *Annals of Oncology.* 2016; 27 (6):416-454.
12. National Comprehensive Cancer Network (NCCN). Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw.* 2017;15:504-535. Accessed May 24, 2017.
13. VENTANA ALK (D5F3) CDx Assay [package insert]. Tucson, Arizona, Roche Laboratories. Ventana Medical Systems, Inc. May 2015.
14. Vysis ALK Break Apart FISH Probe Kit [package insert]. Des Plaines, IL. Abbott Molecular Inc. 2011. Revised April 2015.

15. Wu D, Duan C, Wu F, et al. Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. *Oncotarget*. Sep 12 2017;8(39):66491-66503.
16. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Vysis ALK Break Apart FISH Probe Kit. 2011. Accessed February 4, 2019.
17. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. Dec 4 2014;371(23):2167-2177.
18. Shaw AT, Kim TM, Crino L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. Jul2017;18(7):874-886.